نتایج جستجو برای: alk kinase

تعداد نتایج: 231548  

Journal: :Cancer research 2009
Rajesh R Singh Jeong Hee Cho-Vega Yogesh Davuluri Shuguang Ma Fatan Kasbidi Cristiane Milito Patrick A Lennon Elias Drakos L Jeffrey Medeiros Rajyalakshmi Luthra Francisco Vega

Deregulation of the sonic hedgehog (SHH) signaling pathway has been implicated in several cancers but has not been explored in T-cell lymphomas. Here, we report that the SHH/GLI1 signaling pathway is activated in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). We show that SHH, but not its transcriptional effector GLI1, is amplified in ALK+ ALCL tumors and cell ...

2017
Jikui Guan Yasuo Yamazaki Damini Chand Jesper R van Dijk Kristina Ruuth Ruth H Palmer Bengt Hallberg

Numerous mutations have been observed in the Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase (RTK) in both germline and sporadic neuroblastoma. Here, we have investigated the Y1278S mutation, observed in four patient cases, and its potential importance in the activation of the full length ALK receptor. Y1278S is located in the 1278-YRASYY-1283 motif of the ALK activation loop, which h...

Journal: :Journal of cell science 2005
Jean Y Gouzi Christel Moog-Lutz Marc Vigny Nicole Brunet-de Carvalho

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase essentially and transiently expressed in specific areas of the developing central and peripheral nervous systems. We previously demonstrated that a membrane-bound and constitutively active form of the ALK protein tyrosine kinase (PTK) domain induced the neuron-like differentiation of PC12 cells through specific activation of the mit...

Journal: :Journal of cell science 2004
Akira Motegi Jiro Fujimoto Masaharu Kotani Hitoshi Sakuraba Tadashi Yamamoto

Anaplastic lymphoma kinase (ALK) is a receptor-type protein tyrosine kinase that is expressed preferentially in neurons of the central and peripheral nervous systems at late embryonic stages. To elucidate the role of ALK in neurons, we developed an agonist monoclonal antibody (mAb) against the extracellular domain of ALK. Here we show that mAb16-39 elicits tyrosine phosphorylation of endogenous...

Journal: :Cancer discovery 2012
Hiroyuki Mano

Anaplastic lymphoma kinase (ALK) is a receptor-type protein tyrosine kinase that is currently the focus of much attention in oncology. ALK is rendered oncogenic as a result of its fusion to NPM1 in anaplastic large cell lymphoma, to TPM3 or TPM4 in inflammatory myofibroblastic tumor, to EML4 in non-small cell lung carcinoma, and to VCL in renal medullary carcinoma. It is also activated as a res...

2016
Antonio Passaro Chiara Lazzari Niki Karachaliou Gianluca Spitaleri Alessia Pochesci Chiara Catania Rafael Rosell Filippo de Marinis

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients ...

Journal: :Cancer research 2011
Takaaki Sasaki Jussi Koivunen Atsuko Ogino Masahiko Yanagita Sarah Nikiforow Wei Zheng Christopher Lathan J Paul Marcoux Jinyan Du Katsuhiro Okuda Marzia Capelletti Takeshi Shimamura Dalia Ercan Magda Stumpfova Yun Xiao Stanislawa Weremowicz Mohit Butaney Stephanie Heon Keith Wilner James G Christensen Michel J Eck Kwok-Kin Wong Neal Lindeman Nathanael S Gray Scott J Rodig Pasi A Jänne

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we report two mechanisms of ALK TKI resistance identified from a crizotinib-treated non-small cell lung...

2015
Aulma R Parker Pavankumar N Petluru Vicki L Nienaber Min Zhao Philippe Y Ayala John Badger Barbara Chie-Leon Vandana Sridhar Cheyenne Logan Harry Kochat Frederick H Hausheer

BNP7787 (Tavocept, disodium 2,2'-dithio-bis-ethanesulfonate) is a novel, investigational, water-soluble disulfide that is well-tolerated and nontoxic. In separate randomized multicenter Phase II and Phase III clinical trials in non-small-cell lung cancer (NSCLC) patients, treatment with BNP7787 in combination with standard chemotherapy resulted in substantial increases in the overall survival o...

2015
Assunta Sgambato Francesca Casaluce Antonio Rossi Paolo Maione Paola Claudia Sacco Cesare Gridelli

2015 Targeted therapies based on molecular diagnostics have opened a new era of personalized medicine in lung cancer treatment. Recently, anaplastic lymphoma kinase (ALK) fusion gene emerged as an important biomarker for identifying a small proportion of non-small-cell lung cancer (NSCLC) patients that will benefit from ALK kinase inhibitor crizotinib, like EGFR activating mutations and EGFR ty...

2015
Hideko Isozaki Nagio Takigawa Katsuyuki Kiura Siow Ming Lee

The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib. Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant pat...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید